BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$691M |
| 2 |
Microsoft
MSFT
|
+$544M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$455M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$429M |
| 5 |
Pfizer
PFE
|
+$421M |
Top Sells
| 1 |
Visa
V
|
+$818M |
| 2 |
Lam Research
LRCX
|
+$590M |
| 3 |
Industrial Select Sector SPDR Fund
XLI
|
+$570M |
| 4 |
iShares MSCI ACWI ETF
ACWI
|
+$374M |
| 5 |
SPDR S&P 500 ETF Trust
SPY
|
+$340M |
Sector Composition
| 1 | Technology | 26.44% |
| 2 | Financials | 10.71% |
| 3 | Consumer Discretionary | 10.59% |
| 4 | Healthcare | 9.73% |
| 5 | Communication Services | 7.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2826
Adverum Biotechnologies
ADVM
$69.5M
| $29.1K | ﹤0.01% |
4,146
+2,649
| +177% | +$18.6K |
|
2827
AMREP Corp
AXR
$116M
| $28.9K | ﹤0.01% |
+973
| New | +$28.9K |
|
2828
OptimizeRx
OPRX
$326M
| $28.5K | ﹤0.01% |
3,690
+2,414
| +189% | +$18.6K |
|
2829
PetMed Express
PETS
$56.4M
| $28.4K | ﹤0.01% |
7,705
-8,812
| -53% | -$32.4K |
|
2830
Imperial Oil
IMO
$46.6B
| $28.2K | ﹤0.01% |
+400
| New | +$28.2K |
|
2831
Metagenomi
MGX
$69.1M
| $27.8K | ﹤0.01% |
12,799
+7,256
| +131% | +$15.7K |
|
2832
Biglari Holdings Class B
BH
$951M
| $27.5K | ﹤0.01% |
160
+36
| +29% | +$6.19K |
|
2833
Invesco FTSE RAFI Emerging Markets ETF
PXH
$1.62B
| $27.4K | ﹤0.01% |
+1,250
| New | +$27.4K |
|
|
ALMS
2834
Alumis Inc. Common Stock
ALMS
$447M
| $27.4K | ﹤0.01% |
+2,567
| New | +$27.4K |
|
2835
Critical Metals Corp
CRML
$563M
| $27.3K | ﹤0.01% |
3,674
+1,074
| +41% | +$7.99K |
|
2836
InfuSystem Holdings
INFU
$206M
| $27.3K | ﹤0.01% |
4,076
+1,626
| +66% | +$10.9K |
|
2837
X4 Pharmaceuticals
XFOR
$76.1M
| $27.2K | ﹤0.01% |
1,357
+787
| +138% | +$15.8K |
|
2838
NACCO Industries
NC
$293M
| $27.2K | ﹤0.01% |
959
-325
| -25% | -$9.21K |
|
2839
NI Holdings
NODK
$275M
| $27.1K | ﹤0.01% |
1,731
+122
| +8% | +$1.91K |
|
2840
BioXcel Therapeutics
BTAI
$56.4M
| $27.1K | ﹤0.01% |
2,774
-14,297
| -84% | -$140K |
|
2841
Occidental Petroleum Corporation Warrants to Purchase Common Stock
OXY.WS
$23.1B
| $27K | ﹤0.01% |
908
| – | – |
|
2842
Invesco FTSE RAFI US 1000 ETF
PRF
$8.11B
| $26.7K | ﹤0.01% |
+657
| New | +$26.7K |
|
2843
Cartesian Therapeutics
RNAC
$255M
| $26.6K | ﹤0.01% |
1,651
+909
| +123% | +$14.7K |
|
2844
Mammoth Energy Services
TUSK
$113M
| $26.6K | ﹤0.01% |
6,504
+1,567
| +32% | +$6.41K |
|
2845
Gilat Satellite Networks
GILT
$605M
| $26.6K | ﹤0.01% |
+5,038
| New | +$26.6K |
|
2846
New Mountain Finance
NMFC
$1.11B
| $26.4K | ﹤0.01% |
+2,200
| New | +$26.4K |
|
2847
scPharmaceuticals
SCPH
$301M
| $26.2K | ﹤0.01% |
5,753
+3,101
| +117% | +$14.1K |
|
2848
Sol-Gel Technologies
SLGL
$66.7M
| $25.6K | ﹤0.01% |
3,770
+1,560
| +71% | +$10.6K |
|
|
SBT
2849
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
| $25K | ﹤0.01% |
5,498
+284
| +5% | +$1.29K |
|
2850
Gyre Therapeutics
GYRE
$742M
| $24.4K | ﹤0.01% |
1,947
+1,427
| +274% | +$17.9K |
|